These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 27751354)
1. Mutant TP53 disrupts age-related accumulation patterns of somatic mutations in multiple cancer types. Zhang W; Flemington EK; Zhang K Cancer Genet; 2016 Sep; 209(9):376-380. PubMed ID: 27751354 [TBL] [Abstract][Full Text] [Related]
2. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877 [TBL] [Abstract][Full Text] [Related]
3. Characterizing genomic differences of human cancer stratified by the TP53 mutation status. Wang M; Yang C; Zhang X; Li X Mol Genet Genomics; 2018 Jun; 293(3):737-746. PubMed ID: 29330617 [TBL] [Abstract][Full Text] [Related]
4. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302 [TBL] [Abstract][Full Text] [Related]
5. TP53 mutations, expression and interaction networks in human cancers. Wang X; Sun Q Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943 [TBL] [Abstract][Full Text] [Related]
6. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573 [TBL] [Abstract][Full Text] [Related]
7. Insights into wild-type and mutant p53 functions provided by genetically engineered mice. Donehower LA Hum Mutat; 2014 Jun; 35(6):715-27. PubMed ID: 24415648 [TBL] [Abstract][Full Text] [Related]
8. [TP53 mutations and molecular epidemiology]. Otsuka K; Ishioka C Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437 [TBL] [Abstract][Full Text] [Related]
9. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status. Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952 [TBL] [Abstract][Full Text] [Related]
10. Correlation of telomere length shortening with TP53 somatic mutations, polymorphisms and allelic loss in breast tumors and esophageal cancer. Hao XD; Yang Y; Song X; Zhao XK; Wang LD; He JD; Kong QP; Tang NL; Zhang YP Oncol Rep; 2013 Jan; 29(1):226-36. PubMed ID: 23124483 [TBL] [Abstract][Full Text] [Related]
11. Analysis of full coding sequence of the TP53 gene in invasive vulvar cancers: Implications for therapy. Kashofer K; Regauer S Gynecol Oncol; 2017 Aug; 146(2):314-318. PubMed ID: 28527674 [TBL] [Abstract][Full Text] [Related]
12. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines. Zheng L; Wang F; Qian C; Neumann RM; Cheville JC; Tindall DJ; Liu W Hum Mutat; 2006 Oct; 27(10):1062-3. PubMed ID: 16941491 [TBL] [Abstract][Full Text] [Related]
13. Cancer type-dependent correlations between TP53 mutations and antitumor immunity. Li L; Li M; Wang X DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736 [TBL] [Abstract][Full Text] [Related]
15. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion. Fulci G; Ishii N; Maurici D; Gernert KM; Hainaut P; Kaur B; Van Meir EG Cancer Res; 2002 May; 62(10):2897-905. PubMed ID: 12019170 [TBL] [Abstract][Full Text] [Related]
16. Integrating mutation and gene expression cross-sectional data to infer cancer progression. Fleck JL; Pavel AB; Cassandras CG BMC Syst Biol; 2016 Jan; 10():12. PubMed ID: 26810975 [TBL] [Abstract][Full Text] [Related]
17. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Petitjean A; Achatz MI; Borresen-Dale AL; Hainaut P; Olivier M Oncogene; 2007 Apr; 26(15):2157-65. PubMed ID: 17401424 [TBL] [Abstract][Full Text] [Related]
18. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers. Schultheis AM; Martelotto LG; De Filippo MR; Piscuglio S; Ng CK; Hussein YR; Reis-Filho JS; Soslow RA; Weigelt B Int J Gynecol Pathol; 2016 Jul; 35(4):289-300. PubMed ID: 26556035 [TBL] [Abstract][Full Text] [Related]
19. Mutational processes shape the landscape of TP53 mutations in human cancer. Giacomelli AO; Yang X; Lintner RE; McFarland JM; Duby M; Kim J; Howard TP; Takeda DY; Ly SH; Kim E; Gannon HS; Hurhula B; Sharpe T; Goodale A; Fritchman B; Steelman S; Vazquez F; Tsherniak A; Aguirre AJ; Doench JG; Piccioni F; Roberts CWM; Meyerson M; Getz G; Johannessen CM; Root DE; Hahn WC Nat Genet; 2018 Oct; 50(10):1381-1387. PubMed ID: 30224644 [TBL] [Abstract][Full Text] [Related]
20. Somatic genome alterations in relation to age in lung adenocarcinoma. Meucci S; Keilholz U; Heim D; Klauschen F; Cacciatore S Int J Cancer; 2019 Oct; 145(8):2091-2099. PubMed ID: 30859574 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]